Literature DB >> 23751569

Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors.

Salvatore Vaccarella1, Joannie Lortet-Tieulent, Martyn Plummer, Silvia Franceschi, Freddie Bray.   

Abstract

BACKGROUND: Cervical cancer trends in a given country mainly depend on the existence of effective screening programmes and time changes in disease risk factors, notably exposure to human papillomavirus (HPV). Screening primarily influences variations by period of diagnosis, whereas changes in risk factors chiefly manifest themselves as variations in risk across successive birth cohorts of women.
METHODS: We assessed trends in cervical cancer across 38 countries in five continents, age group 30-74 years, using age-standardised incidence rates (ASRs) and age-period-cohort (APC) models. Non-identifiability in APC models was circumvented by making assumptions based on a consistent relationship between age and cervical cancer incidence (i.e. approximately constant rates after age 45 years).
FINDINGS: ASRs decreased in several countries, except in most of Eastern European populations, Thailand as well as Uganda, although the direction and magnitude of period and birth cohort effects varied substantially. Strong downward trends in cervical cancer risk by period were found in the highest-income countries, whereas no clear changes by period were found in lower-resourced settings. Successive generations of women born after 1940 or 1950 exhibited either an increase in risk of cervical cancer (in most European countries, Japan, China), no substantial changes (North America and Australia) or a decrease (Ecuador and India).
INTERPRETATION: In countries where effective screening has been in place for a long time the consequences of underlying increases in cohort-specific risk were largely avoided. In the absence of screening, cohort-led increases or, stable, cervical cancer ASRs were observed. Our study underscores the importance of strengthening screening efforts and augmenting existing cancer control efforts with HPV vaccination, notably in those countries where unfavourable cohort effects are continuing or emerging. FUNDING: Bill and Melinda Gates Foundation (BMGF).
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age-period-cohort models; Cervical cancer; Impact of screening; Incidence trends

Mesh:

Year:  2013        PMID: 23751569     DOI: 10.1016/j.ejca.2013.04.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  139 in total

1.  Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study.

Authors:  James Brian Szender; Rikki Cannioto; Nicolas R Gulati; Kristina L Schmitt; Grace Friel; Albina Minlikeeva; Alexis Platek; Emily H Gower; Ryan Nagy; Edgar Khachatryan; Paul C Mayor; Karin A Kasza; Shashikant B Lele; Kunle Odunsi; Kirsten B Moysich
Journal:  J Low Genit Tract Dis       Date:  2016-07       Impact factor: 1.925

2.  Trends in cervical cancer incidence and mortality in Poland: is there an impact of the introduction of the organised screening?

Authors:  Andrzej Nowakowski; Urszula Wojciechowska; Paulina Wieszczy; Marek Cybulski; Michał F Kamiński; Joanna Didkowska
Journal:  Eur J Epidemiol       Date:  2017-08-05       Impact factor: 8.082

3.  Soy and tea intake on cervical cancer risk: the Singapore Chinese Health Study.

Authors:  Proma Paul; Woon-Puay Koh; Aizhen Jin; Angelika Michel; Tim Waterboer; Michael Pawlita; Renwei Wang; Jian-Min Yuan; Lesley M Butler
Journal:  Cancer Causes Control       Date:  2019-06-01       Impact factor: 2.506

4.  The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.

Authors:  Norbert Varga; Johanna Mózes; Helen Keegan; Christine White; Lynne Kelly; Loretto Pilkington; Márta Benczik; Schaff Zsuzsanna; Gábor Sobel; Róbert Koiss; Edit Babarczi; Miklos Nyíri; Laura Kovács; Sebe Attila; Borbála Kaltenecker; Adrienn Géresi; Adrienn Kocsis; John O'Leary; Cara M Martin; Csaba Jeney
Journal:  Pathol Oncol Res       Date:  2016-08-06       Impact factor: 3.201

5.  Effect of the national screening program on malignancy status of cervical cancer in Northern Thailand.

Authors:  Shama Virani; Hutcha Sriplung; Surichai Bilheem; Patumrat Sripan; Puttachart Maneesai; Narate Waisri; Imjai Chitapanarux
Journal:  Int J Public Health       Date:  2018-01-23       Impact factor: 3.380

6.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

7.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

8.  Women's Understanding of the Term 'Pap smear': A Comparison of Spanish-Speaking Versus English-Speaking Women.

Authors:  David L Howard; Beth Soulli; Nicole Johnson; Saladin Cooper
Journal:  Matern Child Health J       Date:  2016-11

9.  Association between the p73 gene G4C14-to-A4T14 single nucleotide polymorphism and risk of cervical cancer by high resolution melting and PCR with confronting two-pair primers in a Chinese population.

Authors:  Haiyan Guo; Shaodi Yang; Lijian Xu; Ding Li; Jianxin Tang; Shuangshaung Wang; Benjie Wei; Zhengchun Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

Review 10.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Authors:  F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.